Drugs For Benign Prostatic hypertrophy Market Report 2026

Drugs For Benign Prostatic hypertrophy Market Overview

• Drugs For Benign Prostatic hypertrophy market size has reached to $4.55 billion in 2025 • Expected to grow to $5.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Rising Prevalence Of Prostate Diseases Driving Market Growth Due To Increased Need For Effective Therapeutic Management • Market Trend: New Treatment Option For BPH And ED, Akums Drugs Unveils Cromax Capsule • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Drugs For Benign Prostatic hypertrophy Market?

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibers in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50. The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Drugs For Benign Prostatic hypertrophy Market Growth Forecast?

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increase in male life expectancy, rising healthcare access, innovation in combination drugs, expansion of outpatient urology clinics, lifestyle-related risk factors. Major trends in the forecast period include rising demand from aging male population, increased adoption of combination therapies, growth of minimally invasive drug treatments, expansion of generic bph drugs, growing awareness of early diagnosis.

Global Drugs For Benign Prostatic hypertrophy Market Segmentation

1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users Subsegments: 1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin 2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride 3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil 4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)

What Is The Driver Of The Drugs For Benign Prostatic hypertrophy Market?

The increasing prevalence of prostate diseases is expected to propel the growth of the drugs for benign prostatic hypertrophy market going forward. Prostate diseases refer to a group of medical conditions that affect the prostate gland, a male reproductive organ located just below the bladder. The rise in the prevalence of prostate diseases is primarily attributed to aging and associated metabolic and inflammatory factors that contribute to the development of conditions like benign prostatic hyperplasia (BPH) and prostate cancer. Drugs for benign prostatic hypertrophy (BPH) are important in managing and alleviating urinary symptoms associated with prostate diseases, providing relief by reducing prostate gland enlargement and improving urine flow. For instance, in August 2024, according to Cancer Therapy Advisor, a US-medical information provider, an estimated 299,010 new cases of prostate cancer were expected to be diagnosed in the country in 2024 accounting for 14.9 percent of all new cancer cases with slightly more than 35,000 deaths projected. Therefore, the increased prevalence of prostate diseases is driving the growth of the drugs for benign prostatic hypertrophy industry.

Key Players In The Global Drugs For Benign Prostatic hypertrophy Market

Major companies operating in the drugs for benign prostatic hypertrophy market are Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Pfizer Inc., Ipsen S.A., Novartis International AG, Bayer AG, Merck & Co. Inc., Endo Pharmaceuticals Inc., Impax Laboratories Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Eli Lilly and Company, Bausch Health Companies Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Cipla Ltd

Global Drugs For Benign Prostatic hypertrophy Market Trends and Insights

Major companies operating in the drugs for benign prostatic hypertrophy market are focusing on developing solutions with technological advancement, such as new medication for both enlarged prostate (benign prostatic hyperplasia, BPH) and erectile dysfunction, to gain a competitive edge in the market. Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. And erectile dysfunction (ED) refers to the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an Indian-based paint and coating manufacturing pharmaceutical contract manufacturer, launched Tamsulosin + Tadalafil Capsule to expand its product offerings in the pharmaceutical sector, particularly in areas that address common men's health issues. This innovative product, Cromax, offers unique features such as a dual-action formulation combining Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, and Tadalafil, which enhances blood flow to the penis to facilitate erections. This combination therapy not only provides a more convenient treatment option for men suffering from both benign prostatic hyperplasia (BPH) and erectile dysfunction but also demonstrates significant improvements in the International Prostate Symptom Score (IPSS).

What Are Latest Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market?

In September 2025, Medicus Pharma Ltd., a US-based pharmaceutical company, acquired Antev Limited, for an undisclosed amount. Through this acquisition, Medicus Pharma aims to enhance its drugs for benign prostatic hypertrophy (BPH) portfolio by integrating Antev’s established product offerings and regulatory expertise, enabling the development and commercialization of therapies for prostate health. Antev Limited is a UK-based pharmaceutical company, specializes in urology and BPH treatments and offers drugs for benign prostatic hypertrophy.

Regional Insights

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2025. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Drugs For Benign Prostatic hypertrophy Market?

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drugs For Benign Prostatic hypertrophy Market Report 2026?

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.